BioPharmSignal logoBioPharmSignal

Biotech News

Liquidia Corporation to Participate in Upcoming Investor Conferences

Liquidia Corporation (LQDA)Liquidia CorporationCompany update

MORRISVILLE, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced it will participate in upcoming investor

Related news

LQDALiquidia Corporation2025-11-03 13:00 EST

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

LQDALiquidia Corporation2026-07-29 12:30 EST

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

View all latest news

Liquidia Corporation

Pulmonary Hypertension Company Liquidia develops and commercializes therapies for pulmonary hypertension. Its product strategy applies particle-engineering technology to improve delivery of established medicines. YUTREPIA YUTREPIA is a dry-powder formulation of treprostinil delivered through a compact, low-effort inhaler. It is approved...

Recent company news

LQDALiquidia Corporation2026-08-12 10:30 EST

Liquidia Corporation Reports Second Quarter 2026 Financial Results

LQDALiquidia Corporation2026-07-29 12:30 EST

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

LQDALiquidia Corporation2026-06-11 12:30 EST

Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions

LQDALiquidia Corporation2026-06-08 12:30 EST

Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

LQDALiquidia Corporation2026-05-27 12:30 EST

Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

Stock data

Close
68.62 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States